Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energetics

“Our study identifies why this drug [empagliflozin] is effective – because it improves heart function, something that has not been understood until now. Many doctors are afraid of prescribing a drug they do not understand, and our findings will help clinicians feel more comfortable giving this to patients once approved.”

“So it's not that you inhibit the progression of heart failure, but you can even regress the process. SGLT2 inhibition seems to be an alternative to the treatment of heart failure patients independently of whether there are or there are not diabetics.”

“Many cardiologists want to know mechanisms as well as clinical benefit. These remodeling data showing that these drugs reduce the size of abnormally large hearts [are] also very important for patients. There have been more than 50 publications on potential mechanisms of benefit of SGLT2 inhibitors in HFrEF, but these are the first randomized, mechanistic data.”